AVADEL PHARMACEUTICALS (AVDL) Stock Price, Quote, News and Overview
NASDAQ:AVDL - Nasdaq - IE00BDGMC594 - Common Stock - Currency: USD
AVDL Quote, Performance and Key Statistics
9.15
-0.22 (-2.35%)
The current stock price of AVDL is 9.15 USD. In the past month the price increased by 10.11%. In the past year, price decreased by -41.9%.
AVDL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 52.69 | 687.25B | ||
| JNJ | JOHNSON & JOHNSON | 15.24 | 368.56B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.49 | 302.74B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.57 | 222.75B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.73 | 216.03B | ||
| MRK | MERCK & CO. INC. | 9.88 | 193.71B | ||
| PFE | PFIZER INC | 7.18 | 130.67B | ||
| SNY | SANOFI-ADR | 13.78 | 129.50B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.4 | 95.65B | ||
| GSK | GSK PLC-SPON ADR | 6.99 | 77.98B | ||
| ZTS | ZOETIS INC | 26.82 | 72.01B | ||
| HLN | HALEON PLC-ADR | 22.65 | 50.05B |
Related stock screener links
About AVDL
Company Profile
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 188 full-time employees. The firm's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Company Info
AVADEL PHARMACEUTICALS
Block 10-1 Blanchardstown Corporate Park, Ballycoolin
DUBLIN DUBLIN D02 IE
CEO: Gregory J. Divis
Employees: 188
Phone: 35319015201
AVADEL PHARMACEUTICALS / AVDL FAQ
What is the stock price of AVADEL PHARMACEUTICALS today?
The current stock price of AVDL is 9.15 USD. The price decreased by -2.35% in the last trading session.
What is the ticker symbol for AVADEL PHARMACEUTICALS stock?
The exchange symbol of AVADEL PHARMACEUTICALS is AVDL and it is listed on the Nasdaq exchange.
On which exchange is AVDL stock listed?
AVDL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AVADEL PHARMACEUTICALS stock?
16 analysts have analysed AVDL and the average price target is 17.85 USD. This implies a price increase of 95.08% is expected in the next year compared to the current price of 9.15. Check the AVADEL PHARMACEUTICALS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AVADEL PHARMACEUTICALS worth?
AVADEL PHARMACEUTICALS (AVDL) has a market capitalization of 828.78M USD. This makes AVDL a Small Cap stock.
How many employees does AVADEL PHARMACEUTICALS have?
AVADEL PHARMACEUTICALS (AVDL) currently has 188 employees.
What are the support and resistance levels for AVADEL PHARMACEUTICALS (AVDL) stock?
AVADEL PHARMACEUTICALS (AVDL) has a support level at 9 and a resistance level at 9.4. Check the full technical report for a detailed analysis of AVDL support and resistance levels.
Is AVADEL PHARMACEUTICALS (AVDL) expected to grow?
The Revenue of AVADEL PHARMACEUTICALS (AVDL) is expected to grow by 52.41% in the next year. Check the estimates tab for more information on the AVDL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AVADEL PHARMACEUTICALS (AVDL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AVDL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AVDL, evaluating the profitability, health, valuation and growth aspects
- AVADEL PHARMACEUTICALS (AVDL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AVADEL PHARMACEUTICALS (AVDL) Sales and EPS estimates to see what analysts future expectations are.
- AVADEL PHARMACEUTICALS (AVDL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AVADEL PHARMACEUTICALS (AVDL) Insider and Institutional Ownership to learn about the owners and their transactions.
- AVADEL PHARMACEUTICALS (AVDL) Stock Chart to make your own analysis
- AVADEL PHARMACEUTICALS (AVDL) Latest news and press-releases to stay up to date.
Does AVADEL PHARMACEUTICALS (AVDL) stock pay dividends?
AVDL does not pay a dividend.
When does AVADEL PHARMACEUTICALS (AVDL) report earnings?
AVADEL PHARMACEUTICALS (AVDL) will report earnings on 2025-08-06, before the market open.
What is the Price/Earnings (PE) ratio of AVADEL PHARMACEUTICALS (AVDL)?
AVADEL PHARMACEUTICALS (AVDL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.27).
What is the Short Interest ratio of AVADEL PHARMACEUTICALS (AVDL) stock?
The outstanding short interest for AVADEL PHARMACEUTICALS (AVDL) is 11.82% of its float. Check the ownership tab for more information on the AVDL short interest.
AVDL Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to AVDL. When comparing the yearly performance of all stocks, AVDL is a bad performer in the overall market: 77.41% of all stocks are doing better.
AVDL Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to AVDL. AVDL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
AVDL Financial Highlights
Over the last trailing twelve months AVDL reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS increased by 85.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.73% | ||
| ROE | -35.66% | ||
| Debt/Equity | 0 |
AVDL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to AVDL. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 129.75% and a revenue growth 52.41% for AVDL